ALSO NOTED: Guidant warns on defibrillators; FDA approves new Adderall use;and much more...

> Guidant said one of the recommendations it made to physicians in June designed to correct a problem with its recently recalled implantable defibrillators may actually increase risk to patients. Story

> Shire Pharmaceuticals received FDA approval to market Adderall to treat adolescents. Release

> Alpharma is expanding its warning on Kadian. Release

> Myogen has completed enrollment in its Phase III trial of ambrisentan. Release

And Finally... A new study shows a single dose of the anticancer drug carboplatin is as successful and less toxic than previous testicular cancer  treatments, and it is comparable to radiation in effectiveness. Story

Suggested Articles

The public financing will enable Monopar to start a phase 3 trial of a prophylactic treatment for a side effect of chemoradiotherapy. 

The dispute centers on whether Asa Abeliovich used Alector’s confidential information in connection with his work for Prevail Therapeutics.

GSK poaches Merck KGaA's Martinez-Davis to helm pharma stateside; Bulto named Novartis U.S. pharma head; Allergan's Saunders set for huge parachute.